Quercetin-containing composition for reducing uric acid and improving gout and application of quercetin-containing composition

By using quercetin to promote the growth and aggregation ability of Lactobacillus aureus CML180, the problems of large and poor side effects of existing gout treatment drugs have been solved, and safe and efficient uric acid reduction and gout improvement effects have been achieved.

CN118986959AInactive Publication Date: 2024-11-22JIANGMEN SHENGKANGYAN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410608839.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-16
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing gout treatment drugs have adverse reactions such as liver function damage and rash, and have limited effects on hyperuricemia (HUA), especially in poultry, and intestinal microorganisms are related to HUA. The existing methods have great side effects. Inadequate safety and effectiveness.

Method used

Provide a quercetin-containing composition that enhances its aggregation ability with CML180 auricus, promotes its adhesion to intestinal epithelial cells, significantly reduces uric acid production and Increase uric acid excretion and thus relieve gout.

Benefits of technology

Quercetin significantly reduces serum uric acid levels, reduces liver uric acid production, increases renal uric acid excretion, improves gout symptoms, and is safer and more effective than traditional drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986959A_ABST
    Figure CN118986959A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of gout treatment, in particular to a quercetin-containing composition for reducing uric acid and improving gout and application of the quercetin-containing composition, and the quercetin-containing composition comprises quercetin or pharmaceutically acceptable salt of the quercetin or a composition containing the quercetin or the pharmaceutically acceptable salt of the quercetin. The quercetin, the pharmaceutically acceptable salt of the quercetin or the composition containing the quercetin or the pharmaceutically acceptable salt of the quercetin and a pharmaceutically acceptable carrier are prepared into a pharmaceutically acceptable dosage form, and the composition containing the quercetin or the pharmaceutically acceptable salt of the quercetin and the pharmaceutically acceptable carrier are prepared into a pharmaceutically acceptable dosage form. Growth of lactobacillus avium CML180 is remarkably promoted through quercetin in a dose-dependent mode, hydrophobicity of the lactobacillus avium CML180 and the common aggregation capacity of the lactobacillus avium CML180 and clostridium perfringens are improved, adhesion of the lactobacillus avium CML180 and intestinal epithelial cells Caco-2 is promoted, hyperuricemia is remarkably relieved through the lactobacillus avium CML180, and the lactobacillus avium CML180 can be used as a medicine for treating hyperuricemia. The generation of liver uric acid is reduced and the excretion of kidney uric acid is increased, so that the gout is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gout treatment, and in particular to a quercetin-containing composition for lowering uric acid and improving gout and an application thereof. Background Art

[0002] With the improvement of human living standards, the intake of exogenous purine nucleosides and the production of endogenous purine nucleosides in the human body have increased, leading to hyperuricemia (HUA) or gout, which has become a global disease. HUA is a pre-stage of gout and is directly related to gout. At present, the drugs used in clinical treatment of HUA include drugs that inhibit uric acid synthesis (allopurinol, febuxostat) and drugs that increase uric acid excretion (benzbromarone). However, clinical drug treatment has many contraindications such as liver damage, rash, nausea and other adverse reactions, as well as liver and kidney dysfunction, peptic ulcer and other contraindications. Poultry also suffers from gout, especially in goslings, causing serious economic losses to the breeding industry.

[0003] There is increasing evidence that there is a causal relationship between intestinal microorganisms and HUA or gout. The results of intestinal microbial sequencing of gout patients and healthy individuals showed that multiple bacterial genera were associated with the occurrence of gout. Bacteroides, Holdemania, Anaerotruncus, etc. were positively correlated with the occurrence of gout, while Faecalibacterium, Coprococcus, Ruminococcus, etc. were negatively correlated with the occurrence of gout. Probiotics have been shown to participate in the metabolism of purine and uric acid, reduce the production of uric acid, and thus achieve the effect of relieving HUA or gout. For example, Lactobacillus gasseri PA3 can absorb exogenous purines in the intestine, reduce serum uric acid, and relieve HUA. Compared with the side effects caused by drugs such as benzbromarone or allopurinol, probiotic therapy is a safer, more effective, and more diverse method for treating HUA or gout.

[0004] Studies have shown that the use of prebiotics to regulate intestinal microorganisms may be an effective means of improving HUA or gout. (3,3,4,5,7-pentahydroxyflavone) is a flavonol substance rich in vegetables and fruits, which is considered to be a potential prebiotic with anti-inflammatory and anti-cancer effects. Studies have shown that quercetin can reduce serum uric acid in hyperuricemic mice and has the effect of alleviating human gout. Quercetin has been shown to regulate intestinal flora, increase the abundance of lactic acid bacteria, and reduce the abundance of Clostridium perfringens.

[0005] Therefore, it is necessary to provide a quercetin-containing composition for lowering uric acid and improving gout and its application to solve the above technical problems. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a quercetin-containing composition for lowering uric acid and improving gout and its application.

[0007] The present invention provides a quercetin-containing composition for lowering uric acid and improving gout, comprising quercetin or a pharmaceutically acceptable salt thereof or a composition comprising the quercetin or a pharmaceutically acceptable salt thereof, wherein quercetin can significantly promote the growth of Lactobacillus avium CML180 in a dose-dependent manner, increase the hydrophobicity of Lactobacillus avium CML180 and its ability to co-aggregate with Clostridium perfringens, promote the adhesion of Lactobacillus avium CML180 to intestinal epithelial cells Caco-2, significantly alleviate hyperuricemia through Lactobacillus avium CML180, reduce the production of uric acid in the liver and increase the excretion of uric acid in the kidney, thereby achieving improvement of gout.

[0008] Preferably, the Lactobacillus avium CML180 has a registration number of CGMCC No. 26207 in the General Microbiological Center of China National Microbiological Culture Collection Administration.

[0009] Preferably, the Lactobacillus avium CML180 contains 1601 coding sequences and 52 RNA genes, and among the 85 nucleotide transport and metabolism genes, 5 are potential nucleoside hydrolase genes, among which ORF00069 (named nhy69) has 98.08% similarity with the nucleoside hydrolase gene of Lactobacillus avium DSM20655.

[0010] The invention discloses an application of a quercetin-containing composition for lowering uric acid and improving gout, wherein the quercetin, a pharmaceutically acceptable salt of quercetin or a composition comprising the quercetin or a pharmaceutically acceptable salt thereof is formulated into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable dosage form is one of an injection, an oral solution, a capsule, a tablet or a granule, and the pharmaceutically acceptable dosage form is administered subcutaneously, orally, intramuscularly or intraperitoneally, and the dosage is 100-250 mg / kg per day.

[0011] Compared with the related art, the composition for lowering uric acid and improving gout provided by the present invention and its application have the following beneficial effects:

[0012] The present invention provides a composition containing quercetin, and quercetin significantly promotes the growth of Lactobacillus avium CML180 in a dose-dependent manner, increases the hydrophobicity of Lactobacillus avium CML180 and its ability to co-aggregate with Clostridium perfringens, promotes the adhesion of Lactobacillus avium CML180 to intestinal epithelial cells Caco-2, significantly alleviates hyperuricemia through Lactobacillus avium CML180, reduces the generation of uric acid in the liver and increases the excretion of uric acid in the kidney, thereby achieving improvement of gout. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 Schematic diagram of the alleviating effect of quercetin on HUA in broiler chickens;

[0014] Figure 2 Schematic diagram of the altered gut microbial community in chickens treated with quercetin;

[0015] Figure 3 Schematic diagram of the effect of quercetin on the growth, hydrophobicity, adhesion, co-aggregation ability with Clostridium perfringens and self-aggregation ability of L. aviarius CML180;

[0016] Figure 4 Schematic diagram of the effect of L.aviarius CML180 on the alleviation of HUA in mice and its effect on the expression levels of key genes and proteins in the liver uric acid production pathway;

[0017] Figure 5 Schematic diagram of the gene and protein expression levels of key enzymes in the uric acid excretion pathway in mouse kidney and the effects of L. aviarius CML180 on antibiotic pre-treated mice;

[0018] Figure 6 Schematic diagram of the metabolism of purine nucleosides by L.aviarius CML180 in vitro;

[0019] Figure 7 Schematic diagram of genome sequencing of L. aviarius CML180 and identification of nucleoside hydrolase gene nhy69;

[0020] Figure 8 Schematic diagram of the enzymatic properties of Nhy69.

[0021] Figure 1 A is the serum uric acid content in the HUA broiler model; Figure 1 B is the graph of serum uric acid level after quercetin intervention; Figure 1 C is a graph of serum creatinine content; Figure 1 D is the urea nitrogen content diagram, Figure 1 E is the xanthine oxidase activity graph of the liver; Figure 1 F is the graph of serum xanthine oxidase activity; Figure 1G is HE staining of liver and kidney tissues;

[0022] Figure 2 AE are the ACE index, Chao 1 index, Obs index, Shannon index, and Simpson index graphs of the microbial community; Figure 2 F is the beta diversity (NMDS) graph; Figure 2 G and H are LEfSe analysis of differences between groups; Figure 2 I is the Spearman correlation analysis diagram between the intestinal microbiota and uric acid, creatinine, and urea nitrogen parameters in the control group, HUA group, and quercetin group;

[0023] Figure 3 A is an electron microscope photo of L. aviarius CML180; Figure 3 B is a schematic diagram showing the effect of different concentrations of quercetin on the growth of L. aviarius CML180; Figure 3 C is a schematic diagram showing the effect of different concentrations of quercetin on the hydrophobicity of L. aviarius CML180; Figure 3 D is a schematic diagram of the effect of quercetin on the adhesion of L. aviarius CML180 and Caco-2 cells; Figure 3 E is a schematic diagram showing the effect of quercetin on the coaggregation ability of L. aviarius CML180 and Clostridium perfringens; Figure 3 F is a schematic diagram of the effect of quercetin on the self-aggregation ability of L. aviarius CML180;

[0024] Figure 4 AD are serum uric acid, serum creatinine, serum urea nitrogen, and liver xanthine oxidase activity in mice; Figure 4 E is the HE staining image of liver and kidney tissues; Figure 4 F is the mRNA and protein (G) levels of NT5E; Figure 4 H is the mRNA and protein (I) levels of ADA;

[0025] Figure 5 AB are the mRNA and protein levels of mOAT3 in kidney, respectively; Figure 5 CD are the mRNA and protein levels of mOCTN2 in kidney, respectively; Figure 5 EF are the mRNA and protein levels of renal mUMOD; Figure 5 G is the mRNA level of hepatic IL-1β; Figure 5 H is the mRNA level of renal IL-1β. Figure 5 IK are serum uric acid, serum creatinine, and urea nitrogen in antibiotic-pretreated mice;

[0026] Figure 6AC are the degradation rates of uric acid, adenosine, and inosine by L. aviarius CML180, respectively; Figure 6 DE HPLC analysis of adenosine and inosine degradation by L.aviarius CML180;

[0027] Figure 7 A is the genome map of L. aviarius CML180; Figure 7 B is the phylogenetic tree of L. aviarius CML180 and other Lactobacillus avium; Figure 7 C is the COG analysis of the genome of L. aviarius CML180; Figure 7 D is a sequence alignment of Nhy69 and other lactic acid bacterial nucleoside hydrolases;

[0028] Figure 8 A is the substrate specificity of Nhy69; Figure 8 is the enzyme activity of Nhy69 at different temperatures; Figure 8 C is the enzyme activity of Nhy69 at different pH values. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Generally, the components of the embodiments of the present invention described and shown in the drawings here can be arranged and designed in various different configurations.

[0030] Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] It should be noted that similar reference numerals and letters denote similar items in the following drawings, and therefore, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.

[0032] The following is a detailed description of a quercetin-containing composition for lowering uric acid and improving gout and the specific implementation of its application in conjunction with specific embodiments.

[0033] The present invention provides a quercetin-containing composition for lowering uric acid and improving gout, comprising: quercetin or a pharmaceutically acceptable salt thereof or a composition comprising the quercetin or a pharmaceutically acceptable salt thereof, wherein quercetin can significantly promote the growth of Lactobacillus avium CML180 in a dose-dependent manner, increase the hydrophobicity of Lactobacillus avium CML180 and its ability to co-aggregate with Clostridium perfringens, promote the adhesion of Lactobacillus avium CML180 to intestinal epithelial cells Caco-2, significantly alleviate hyperuricemia through Lactobacillus avium CML180, reduce the production of uric acid in the liver and increase the excretion of uric acid in the kidney, thereby achieving improvement of gout.

[0034] It should be noted that the Lactobacillus avium CML180 has a registration number of CGMCC No. 26207 in the General Microbiology Center of the China National Microbiological Culture Collection Administration. The Lactobacillus avium CML180 contains 1,601 coding sequences and 52 RNA genes, and among the 85 nucleotide transport and metabolism genes, 5 are potential nucleoside hydrolase genes, among which ORF00069 (named nhy69) has 98.08% similarity with the nucleoside hydrolase gene of Lactobacillus avium DSM20655.

[0035] The invention discloses an application of a quercetin-containing composition for lowering uric acid and improving gout, wherein the quercetin, a pharmaceutically acceptable salt of quercetin or a composition comprising the quercetin or a pharmaceutically acceptable salt thereof is formulated into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable dosage form is one of an injection, an oral solution, a capsule, a tablet or a granule, and the pharmaceutically acceptable dosage form is administered subcutaneously, orally, intramuscularly or intraperitoneally, and the dosage is 100-250 mg / kg per day.

[0036] Verification experiment

[0037] Quercetin relieves HUA (hyperuricemia) in broiler chickens

[0038] In order to study the effect of quercetin in alleviating HUA, HUA models were established by intragastric administration of adenine and ethambutol hydrochloride and by intragastric administration of adenine and yeast powder.

[0039] In specific implementation, the HUA model constructed by intragastric administration of adenine and yeast powder was more effective and stable than the intragastric administration of adenine and ethambutol hydrochloride. With the continuous intragastric administration of adenine and yeast powder, the serum uric acid level of broiler chickens continued to increase. Compared with the control group, the serum uric acid level of broiler chickens at 49 days of age was significantly increased (P<0.001; Figure 1 A).

[0040] Subsequently, gavage of adenine and yeast powder was used as a modeling method, and quercetin was given to establish the HUA broiler model. After 7 weeks of treatment, quercetin significantly reduced the serum uric acid level of chickens (P<0.05; Figure 1 B), creatinine level (P < 0.01; Figure 1 C), urea nitrogen level (P < 0.001; Figure 1 D), liver xanthine oxidase activity (P<0.05; Figure 1 E), serum xanthine oxidase activity (P<0.05; Figure 1 F). Pathological sections of the liver of HUA broilers showed enlarged interstitial space and dilated hepatic sinusoids, which were alleviated after quercetin intervention ( Figure 1 G). Pathological sections of kidneys of HUA broilers showed edema of renal tubular epithelial cells, pale cytoplasm, and narrowing of the proximal tubule lumen. Quercetin effectively improved these pathological symptoms ( Figure 1 G).

[0041] In summary, we successfully established a broiler HUA model using adenine and yeast powder and found that quercetin has a significant effect in alleviating HUA.

[0042] Compared with the HUA model group, quercetin intervention significantly reduced α diversity indices, including ACE, Chao1, Obs, and Shannon ( Figure 2 AD), while there was no significant difference in Simpson index ( Figure 2 E). Quercetin also altered the beta diversity of the intestinal flora: ( Figure 2 F). LEfSe analysis showed that L.aviarius was the bacterium with the highest abundance difference ( Figure 2 G and H). Correlation analysis between key serum indicators of HUA and intestinal microorganisms showed that L. aviarius was significantly negatively correlated with serum uric acid content (Figure I). In addition, co-occurrence network analysis showed that there were differences in microbial interactions among the three groups; in the quercetin-treated group, L. aviarius had the highest degree of connectivity, further indicating its central role in intestinal microbial interactions in quercetin-treated HUA broilers.

[0043] Compared with the control group, the HUA group had 54 significantly different microbial metabolic pathways (P<0.05), of which 7 microbial metabolic pathways were related to nucleoside and purine metabolism, including histidine, purine and pyrimidine biosynthesis pathways, purine ribonucleoside degradation pathways, and adenosine deoxyribonucleoside de novo biosynthesis pathways. After quercetin intervention, 62 microbial metabolic pathways were changed (P<0.05), among which the differences in purine nucleotide degradation pathways and adenosine nucleotide degradation pathways were the most significant. In addition, other pathways related to nucleoside and purine metabolism, such as inosine-5-phosphate biosynthesis I pathway, guanosine ribonucleotide biosynthesis pathway, and adenosine ribonucleotide biosynthesis pathway, were significantly increased in the quercetin group.

[0044] In conclusion, quercetin intervention alleviated the symptoms of HUA broilers and improved the structure and function of the cecal microbial community in chickens. Quercetin may alleviate HUA by enriching L. aviarius and regulating nucleoside and purine metabolism.

[0045] Quercetin promotes the growth of L.aviarius (Lactobacillus avium) CML180 and enhances its adhesion, hydrophobicity and coaggregation ability

[0046] A strain of L.aviarius was isolated from the cecal contents of broiler chickens treated with quercetin and named CML180. L.aviarius CML180 is nearly spherical ( Figure 3 A), the plate growth showed a matte surface, neat edges, milky white translucent small colonies. We then studied the effect of quercetin on the biological characteristics of L. aviarius CML180, and examined its growth, adhesion to intestinal epithelial cells and coaggregation ability. Different concentrations of quercetin promoted the in vitro growth of L. aviarius CML180 to varying degrees, and the best effect was achieved when the concentration of quercetin was 0.0125 mg / ml ( Figure 3 B). Different concentrations of quercetin significantly increased the hydrophobicity of L.aviarius CML180 (P<0.01), and the quercetin concentration of 0.05 mg / ml had the most significant effect on the hydrophobicity of L.aviarius CML180 ( Figure 3 C). Adhesion experiments showed that quercetin at a concentration of 0.00625 mg / ml could significantly enhance the adhesion of L. aviarius CML180 to Caco-2 cells ( Figure 3 D). In addition, quercetin increased the coaggregation ability of L.aviarius CML180 against Clostridium perfringens ( Figure 3 E), but did not increase the self-aggregation ability of L.aviarius CML180 ( Figure 3 F).

[0047] Lactobacillus aviarius CML180 reduces uric acid levels in HUA mice

[0048] Kunming mice were selected as another model animal of HUA.

[0049] Oral administration of L.aviarius CML180 significantly reduced the serum uric acid level in HUA model mice (P<0.05) ( Figure 4 A), inosine ( Figure 4 B) and urea nitrogen ( Figure 4 C) level (P<0.05) and hepatic xanthine oxidase activity (P<0.01) ( Figure 4 D).

[0050] In addition, it can be seen from the pathological sections that L.aviarius CML180 can alleviate pathological damage such as inflammatory cell infiltration and cell edema in the liver and kidneys ( Figure 4 E).

[0051] The expression of key enzymes involved in uric acid formation at the mRNA and protein levels was further studied. The results showed that L. aviarius CML180 significantly reduced the expression of NT5E ( Figure 4 F and 4G), ADA( Figure 4 H and 4I) and PNPase ( Figure 4 J and 4K) expression.

[0052] In addition, L. aviarius CML180 also reduced the expression of genes related to renal excretion of uric acid, including the urate transporter OAT3 (protein level) ( Figure 5 A and B) and OCTN2( Figure 5 C and 6D), but did not affect the expression of uromodulin factor UMOD protein level ( Figure 5 E and F). L.aviarius CML180 also significantly reduced the gene expression of IL-1β in liver and kidney tissues ( Figure 5 G and H).

[0053] To further confirm the alleviating effect of L.aviarius CML180 on HUA, we conducted an experiment on antibiotic pre-treated mice. Similar to the results of mice with normal intestinal microbiota, L.aviarius CML180 could significantly reduce the serum uric acid level of antibiotic pre-treated mice (P<0.05) ( Figure 5 I), creatinine ( Figure 5 J) and urea nitrogen ( Figure 5 K) content (P<0.001).

[0054] Taken together, these results indicate that L. aviarius CML180 significantly alleviated HUA in mice, reduced hepatic uric acid production and increased renal uric acid excretion.

[0055] The ability of L.aviarius CML180 to metabolize uric acid was studied. The results showed that L.aviarius CML180 could not metabolize or degrade uric acid ( Figure 6 A). We then investigated the metabolic capacity of L. aviarius CML180 on uric acid precursors - purine nucleosides (inosine and adenosine).

[0056] The results showed that inosine (1 g / L) and adenosine (1 g / L) were completely depleted after incubation with L.aviarius CML180 at 37°C for 24 h, indicating that L.aviarius CML180 effectively utilized or degraded these two purine nucleosides ( Figure 6 B and D and Figure 6 C and E).

[0057] These results suggest that the alleviating effect of L. aviarius CML180 on HUA is not due to the direct metabolism of uric acid by L. aviarius CML180, but rather to its metabolism of uric acid precursor purine nucleosides.

[0058] Whole genome sequencing of L. aviarius CML180 and identification of the nucleoside hydrolase gene nhy69

[0059] The whole genome of L. aviarius CML180 was sequenced. The draft genome size is 1689796 bp, containing 1601 coding sequences (CDS) and 52 RNA genes ( Figure 7 A). Phylogenetic analysis of strain CML180 and 21 other L. aviarius strains showed that the closest relatives to L. aviarius CML180 were two chicken-derived L. aviarius strains: ChiW2-1384 and NBRC102162 ( Figure 7 B). In the genome of L. aviarius CML180, a total of 1116 protein-coding genes were annotated by COG. Among them, genes with unknown functions (S: unknown function) accounted for the highest proportion of the total number of genes (21.2%), followed by genes with replication, recombination, and repair functions (L) and genes related to nucleotide transport and metabolism (F) ( Figure 7C). Among the 85 genes for nucleotide transport and metabolism, 5 were potential nucleoside hydrolase genes, among which ORF00069 (named nhy69) had 98.08% similarity with the nucleoside hydrolase gene of L. aviarius DSM 20655 (GCF-001436315.1). This gene was highly conserved among different L. aviarius isolates: all 21 L. aviarius genomes in the NCBI database contained the nhy69 gene, with nucleotide sequence similarities ranging from 97.76% to 98.72%. Protein sequences similar to Nhy69 also exist in other lactic acid bacteria, with similarities ranging from 34.83% in L. gallinarum DSM 10532 to 62.7% in L. delbrueckii subsp. Lactis ( Figure 7 D).

[0060] Based on the above, it is speculated that Nhy69 is a key hydrolase involved in nucleoside metabolism in L. aviarius CML180. In order to verify the nucleoside degradation function of Nhy69, we cloned and expressed the nhy69 gene in Escherichia coli BL21 and purified the protein product. Cytidine, xanthosine, uridine, inosine, guanosine and adenosine were used as substrates, and the specificity of Nhy69 substrate hydrolysis was determined at 37°C and pH 7.

[0061] The results showed that Nhy69 had different hydrolysis abilities for different substrates. It had the strongest degradation activity for guanosine and adenosine, followed by cytidine, xanthosine and inosine, while it had the weakest activity for uridine ( Figure 8 A). The relative enzyme activity results at different temperatures (4-70°C) showed that as the temperature increased, the enzyme activity of Nhy69 continued to increase from 4°C, reaching a peak at 25°C, and then decreased or remained stable as the temperature increased to 37°C. When the temperature increased to 50°C, the enzyme activity disappeared ( Figure 8 B). The results of relative enzyme activity at different pH values ​​(PH 3-11) showed that the enzyme activity of Nhy69 gradually increased with the increase of pH value, reached a peak at pH 5, and then gradually decreased with the further increase of pH value. At pH 9, the enzyme activity was basically lost ( Figure 8 C).

[0062] These results indicate that Nhy69 is a nucleoside hydrolase that uses purine nucleosides as substrates and has high activity under mesophilic and neutral pH conditions.

[0063] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made using the contents of the present invention specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A quercetin-containing composition for lowering uric acid and improving gout, characterized in that: include: Quercetin or a pharmaceutically acceptable salt thereof or a composition comprising the quercetin or a pharmaceutically acceptable salt thereof, wherein quercetin can significantly promote the growth of Lactobacillus avium CML180 in a dose-dependent manner, increase the hydrophobicity of Lactobacillus avium CML180 and its ability to co-aggregate with Clostridium perfringens, promote the adhesion of Lactobacillus avium CML180 to intestinal epithelial cells Caco-2, and significantly alleviate hyperuricemia through Lactobacillus avium CML180, reduce the production of uric acid in the liver and increase the excretion of uric acid in the kidney, thereby achieving improvement in gout.

2. A quercetin-containing composition for lowering uric acid and improving gout according to claim 1, characterized in that: The registration number of the Lactobacillus avium CML180 in the General Microbiological Center of China Culture Collection Administration is CGMCC No. 26207.

3. A quercetin-containing composition for lowering uric acid and improving gout according to claim 2, characterized in that: The Lactobacillus avium CML180 contains 1601 coding sequences and 52 RNA genes, and among the 85 nucleotide transport and metabolism genes, 5 are potential nucleoside hydrolase genes, among which ORF00069 has 98.08% similarity with the nucleoside hydrolase gene of Lactobacillus avium DSM20655.

4. An application of a quercetin-containing composition for lowering uric acid and improving gout, characterized in that: The quercetin, the pharmaceutically acceptable salt of quercetin or the composition comprising the quercetin or the pharmaceutically acceptable salt thereof is formulated into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier.

5. The use of a quercetin-containing composition for lowering uric acid and improving gout according to claim 4, characterized in that: The pharmaceutically acceptable dosage form is one of injection, oral solution, capsule, tablet or granule.

6. The use of a quercetin-containing composition for lowering uric acid and improving gout according to claim 5, characterized in that: The pharmaceutically acceptable dosage form is administered subcutaneously, orally, intramuscularly or intraperitoneally, and the dosage is 100-250 mg / kg per day.

7. The use of a quercetin-containing composition for lowering uric acid and improving gout according to claim 4, characterized in that: The quercetin-containing pharmaceutical composition is used to promote the growth of Lactobacillus avium CML180, and to increase the hydrophobicity of Lactobacillus avium CML180 and its ability to co-aggregate with Clostridium perfringens.

Citation Information

Cited By

  • Application of quercetin in preparation of medicine for improving kidney injury caused by hyperuricemia

    CN120713890A

  • Astaxanthin and dihydroquercetin co-loaded liposome and application thereof in preparation of uric acid reducing product

    CN122140629A